Literature DB >> 11054711

Metallothionein in human gastrointestinal cancer.

A M Janssen1, W van Duijn, M M Oostendorp-Van De Ruit, L Kruidenier, C B Bosman, G Griffioen, C B Lamers, J H van Krieken, C J van De Velde, H W Verspaget.   

Abstract

Metallothionein (MT) is a small thiol-rich metalloprotein with antioxidant properties, involved in tumour pathophysiology and therapy resistance. In order to assess the contribution of MT in gastrointestinal carcinogenesis, this study examined both the MT content by radioimmunoassay and the MT localization by immunohistochemistry in pairs of neoplastic and normal-appearing human gastrointestinal tissues. In addition, the relationship between MT expression and major clinicopathological parameters was assessed. The MT concentration of gastric carcinomas and of colorectal adenomas, carcinomas, and liver metastases was found to be significantly lower than that of corresponding normal-appearing tissue. A relatively high MT content, however, was found to be associated with the villous character of colorectal adenomas and with the Dukes' stage of colorectal carcinomas, indicating a relationship between MT level and malignant potential. Immunohistochemical evaluation showed a fairly good correlation with these quantitative data. MT was found to be expressed at a low level and in a patchy pattern in the gastrointestinal neoplastic and metastatic tissues, whereas in normal-appearing gastrointestinal mucosa MT was uniformly distributed in the cytoplasm and/or nucleus of apical cells. Although in the gastric cancer patients no association was found between the MT concentration and the clinicopathological parameters, the strong MT expression in areas with intestinal metaplasia, known to have neoplastic potential, further points to a relationship between this antioxidant metalloprotein and the malignant character of cells. Gastrointestinal neoplasms are apparently accompanied by a low level and decreased expression of MT, but those with a relatively high level seem to have an increased malignant potential. Further studies will be required to determine the clinical relevance of these observations. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11054711     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH712>3.0.CO;2-Z

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.

Authors:  M Takahashi; D R Rhodes; K A Furge; H Kanayama ; S Kagawa; B B Haab; B T Teh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  Metallothionein expression in hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Lian-Yue Yang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma.

Authors:  Klaus Jürgen Schmitz; Carmen Ina Müller; Henning Reis; Hakan Alakus; Günther Winde; Hideo Andreas Baba; Jeremias Wohlschlaeger; Bharat Jasani; Joachim Fandrey; Kurt Werner Schmid
Journal:  Int J Colorectal Dis       Date:  2009-06-16       Impact factor: 2.571

4.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

5.  Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells.

Authors:  Juan Martín Arriaga; Alicia Inés Bravo; José Mordoh; Michele Bianchini
Journal:  Oncol Rep       Date:  2017-04-03       Impact factor: 3.906

6.  SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.

Authors:  R Tiwari; S K Pandey; S Goel; V Bhatia; S Shukla; X Jing; S M Dhanasekaran; B Ateeq
Journal:  Oncogenesis       Date:  2015-08-10       Impact factor: 7.485

7.  Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.

Authors:  Yuanming Pan; Shuye Lin; Rui Xing; Min Zhu; Bonan Lin; Jiantao Cui; Wenmei Li; Jing Gao; Lin Shen; Yuanyuan Zhao; Mingzhou Guo; Ji Ming Wang; Jiaqiang Huang; Youyong Lu
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

8.  Evaluation of MT Family Isoforms as Potential Biomarker for Predicting Progression and Prognosis in Gastric Cancer.

Authors:  Mingfu Tong; Wenquan Lu; Hao Liu; Jian Wu; Mingzuo Jiang; Xin Wang; Jianyu Hao; Daiming Fan
Journal:  Biomed Res Int       Date:  2019-07-17       Impact factor: 3.411

9.  Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma.

Authors:  P Coyle; G Mathew; P A Game; J C Myers; J C Philcox; A M Rofe; G G Jamieson
Journal:  Br J Cancer       Date:  2002-08-27       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.